5 minute read
May 1, 2022

Why Did GSK Pay $1.9B for Momelotinib, an Oral Ph. III Myelofibrosis Candidate?

Drug Hunter Team

Momelotinib, an oral JAK1/2 inhibitor for myelofibrosis, is going to GSK as part of a $1.9 billion acquisition of Sierra Oncology. Anyone that’s ever worked on a kinase program probably looked at this structure and raised their eyebrows. $1.9 billion for another JAK2 inhibitor? It’s probably not super selective either, you might think… and you’d be right. But details here are actually pretty interesting.



Other articles you may be interested in